To the best of our knowledge, the OPTIMA study will be the first study to evaluate tumor molecular profiling, UGT1A1 genotype and GUS activity as potential biomarkers for efficacy and toxicity of irinotecan-based systemic treatment in patients with advanced CRC. Here, UGT1A1 is linked to colorectal carcinoma.